Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice by Bock, Oliver & Felsenberg, Dieter
© 2008 Dove Medical Press Limited.   All rights reserved
Clinical Interventions in Aging 2008:3(2) 279–297 279
REVIEW
Bisphosphonates in the management of 
postmenopausal osteoporosis – optimizing 
efﬁ  cacy in clinical practice
Oliver Bock
Dieter Felsenberg
Center for Muscle and Bone 
Research, Campus Benjamin Franklin, 
Charité – University Medicine Berlin, 
Berlin, Germany
Correspondence: Oliver Bock
Charité – Campus Benjamin Franklin, 
Center for Muscle and Bone Research, 
Hindenburgdamm 30, D-12200 Berlin, 
Germany
Tel +49 30 8445-3891
Fax +49 30 7935502
Email oliver.bock@charite.de
Abstract: Nitrogen-containing bisphosphonates are potent inhibitors of osteoclastic bone 
resorption. With their individually proven efﬁ  cacy to signiﬁ  cantly reduce the incidence of 
vertebral and/or non-vertebral fractures and with their overall beneﬁ  cial safety proﬁ  le, alen-
dronate, ibandronate, risedronate, and zoledronate are considered today a treatment of ﬁ  rst 
choice in postmenopausal osteoporosis. However, treatment effects in an individual patient and 
cost-effectiveness in public health perspective are vitally dependent on the long-term patient 
adherence as well as on compliance and persistence. As compliance and persistence with daily 
oral bisphosphonates are shown to be suboptimal in many patients, leading to an increased 
fracture incidence in non-compliant patients, there is a need to improve overall adherence for 
bisphosphonate treatment in order to achieve maximum treatment effects. One option is to extend 
dosing intervals to weekly (alendronate, risedronate) or monthly (ibandronate) oral regimens. 
Less frequent oral regimens are generally preferred by majority of patients. Another alternative 
is intravenous, instead of oral application (ibandronate, zoledronate). Treatment acceptance 
could be further improved by IV bisphosphonates with their beneﬁ  t of only quarterly, or even 
once-yearly, application. Treatment decisions should be based on anti-fracture efﬁ  cacy data 
ﬁ  rst. In addition, to ensure best possible patient adherence and maximum treatment beneﬁ  ts, 
physicians should consider individual patient conditions affecting compliance and persistence 
as well as patient preferences.
Keywords: postmenopausal osteoporosis, bisphosphonates, fracture risk reduction, adherence, 
dosing frequencies, patient considerations
Introduction
Osteoporosis is a disease characterized by low bone mass and micro architectural 
deterioration of bone tissue, leading to enhanced bone fragility and increased suscep-
tibility to fractures (NIH 2001; WHO 2003a). Most common osteoporosis-related, 
non-trauma-based, fractures affect spine (vertebral bodies), hip, wrist, and humerus, 
although they can occur at almost any skeletal site.
Osteoporosis is considered a serious public health concern due to its important 
worldwide prevalence. Currently it is estimated that over 200 million people worldwide 
suffer from this disease (Cooper 1999). Approximately 30% of all postmenopausal 
women have osteoporosis in the United States and in Europe. Available data for the 
year 2000 point out to 9.0 million osteoporotic fractures, 1.6 million of which were 
at the hip, 1.7 million at the forearm, and 1.4 million were clinical vertebral fractures. 
The greatest number of osteoporotic fractures occurred in Europe (34.8%) (Johnell and 
Kanis 2006). In Germany in 2003, 7.8 million persons (6.5 million women, 1.3 million 
men) were affected by osteoporosis and 4.3% of them experienced at least one clinical 
fracture. The total direct costs attributable to osteoporosis amounted to €5.4 billion. 
Furthermore, the BonEVA Study conﬁ  rmed that osteoporosis was underdiagnosed, Clinical Interventions in Aging 2008:3(2) 280
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undertreated and imposed a considerable economic burden 
on the health system (Häussler et al 2007).
Aging of populations worldwide will also contribute to a 
major increase of the incidence of osteoporosis in postmeno-
pausal women (Reginster and Burlet 2006). About 40%–50% 
of women and 13%–30% of men will sustain one or more 
fragility fractures in their remaining lifetime (Melton et al 
1992; Randell et al 1995; Johnell and Kanis 2005; Nguyen 
et al 2007).
By 2050, the worldwide incidence of hip fracture is 
expected to increase by 240% in women and 310% in men 
(Gullberg et al 1997). The estimated number of hip fractures 
worldwide will rise from 1.66 million in 1990 to 6.26 million 
in 2050, even though the age-adjusted incidence rates will 
remain stable (Sambrook and Cooper 2006).
Osteoporosis may result in acute and chronic pain, dis-
abilities, restricted movement until immobilization, impaired 
quality of life as well as social isolation. It is far more com-
mon than other diseases, which commonly capture public 
attention, eg, the combined lifetime risk of hip, forearm, and 
vertebral fractures coming to clinical attention is equivalent 
to the risk posed by cardiovascular diseases (Kanis 2002). In 
women over 45 years of age, osteoporosis accounts for more 
days in hospital than may other diseases, including diabetes, 
myocardial infarction, and breast cancer (Kanis et al 1997).
The total Disability Adjusted Life Years (DALYs) loss 
was 5.8 million of which 51% were accounted for by frac-
tures that occurred in Europe and the Americas. Osteoporotic 
fractures accounted for 0.83% of the global burden of non-
communicable disease worldwide and for 1.75% in Europe. 
Here, osteoporotic fractures accounted for more DALYs 
loss than common cancers, with the exception of lung cancer 
(Johnell and Kanis 2006). Although osteoporosis is often asso-
ciated with increased mortality, it remains under-recognized. 
Importantly, in 1990, 740,000 deaths worldwide were associ-
ated with hip fracture (Johnell and Kanis 2004). Many other 
studies have shown increase in mortality in connection with 
osteoporotic fractures (Cooper et al 1993; Center et al 1999; 
Johnell and Haglund 1999; Cauley et al 2000; Johnell et al 
2004). This has been best characterized following hip fracture 
(Weiss et al 1983; Magaziner et al 1989; Sernbo and Johnell 
1993; Todd et al 1995; Browner et al 1996; Melton et al 1998; 
Forsén et al 1999), but several recent studies of vertebral frac-
ture, eg, Study of Osteoporotic Fractures (SOF) and European 
Prospective Osteoporosis Study (EPOS), have also indicated 
higher mortality in affected patients as opposed to the general 
population (Ismail et al 1998; Kado et al 1999; Ensrud et al 
2000; Hasserius et al 2003; Johnell et al 2004).
The objective of treatment in patients with postmenopausal 
osteoporosis is to reduce the risk of fractures and to prevent 
the impairment of quality of life as well as to reduce osteo-
porosis-related mortality. The clinical efﬁ  cacy of new drugs 
to treat osteoporosis must be judged in clinical trials that use 
the reduction of fracture risk as the main end point, rather than 
trials that use surrogate end points, such as changes in bone 
mineral density (BMD) (Chapurlat and Delmas 2006).
Management of osteoporosis 
with nitrogen-containing 
bisphosphonates
Nitrogen-containing bisphosphonates are highly potent 
inhibitors of osteoclastic bone resorption and the ﬁ  rst class 
of drugs that unequivocally demonstrated their ability to 
reduce vertebral fracture risk in good-quality clinical trials 
(alendronate: Black et al 1996; Cummings et al 1998; rise-
dronate: Harris et al 1999; Reginster et al 2000; ibandronate: 
Chesnut et al 2004; zoledronate: Black et al 2007). Today, 
they are often the ﬁ  rst-line therapy for postmenopausal 
osteoporosis worldwide.
Additionally, alendronate and risedronate are considered 
to be the only antiresorptive agents shown in meta-analyses 
to signiﬁ  cantly reduce the risk of non-vertebral fractures 
(Cranney et al 2002; Boonen et al 2005). In prospective 
analyses, risedronate has demonstrated to reduce hip fracture 
incidence (McClung et al 2001), and zoledronate recently 
has shown robust data for non-vertebral and hip fracture 
risk reduction in addition to profound effects on decreased 
vertebral fracture incidence (Black et al 2007).
So far, oral bisphosphonates such as alendronate, risedro-
natem and ibandronate have come to be the most widely used 
drugs in the treatment of osteoporosis, whereas the newer 
intravenous bisphosphonates, such as ibandronate and zoledro-
nate, are about to round off the overall beneﬁ  cial potential of 
bisphosphonate treatment in postmenopausal osteoporosis.
The fracture risk reduction as well as the increase in BMD 
and improvement of structural bone properties induced by 
bisphosphonates seem to be related to the profound inhibi-
tion of osteoclastic bone resorption with an initial ﬁ  lling of 
the remodeling space (resorption lacuna), followed by an 
increased degree of mineralization that results from the glob-
ally slowed down rate of bone turnover (Boivin et al 2000).
Pharmacology of bisphosphonates
Bisphosphonates are chemical P–C–P analogs of inorganic 
pyrophosphate, which is characterized by a P–O–P structure. Clinical Interventions in Aging 2008:3(2) 281
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Thus the P–C–P structure is resistant to enzymatic degrada-
tion by pyrophosphatase (see Figure 1).
Bisphosphonates have a high binding afﬁ  nity to hydroxy-
apatite, are internalized by osteoclasts through endocytosis, 
and inhibit bone resorption by cellular effects that impair 
osteoclast recruitment, differentiation, and action on the bone 
surface (Chapurlat and Delmas 2006).
Although the various bisphosphonates share many phar-
macologic features, important biochemical differences exist 
among them, particularly in the way in which they bind to 
bone mineral and their effects on bone resorption. These dif-
ferences may account for some of the observed variations in 
potency, disease-speciﬁ  c efﬁ  cacy, safety patterns, and speed 
of onset and offset of action (Russell 2007).
Pharmacodynamics
As a class, all bisphosphonates work through the binding of 
the phosphonate groups to hydroxyapatite. Bisphosphonates 
have a common P–C–P backbone, where C is carbon and P 
represents a phosphonate group. The presence of 2 phospho-
nate groups allows the molecule to act as a “bone hook” and is 
essential for targeting bone and for the molecular mechanism 
of action of the compounds.
Bisphosphonates have 2 side groups: R1 and R2. When 
the R1 side group is a hydroxyl group, as it is in all com-
monly used bisphosphonates, it enables enhanced binding 
to bone.
It is the differences in the R2 side group, however, that 
account for the signiﬁ  cant disparities between the various 
bisphosphonates. Second-generation bisphosphonates con-
tain a nitrogen side group, in the form of an amino group, 
whereas earlier bisphosphonates have no nitrogen group in 
the R2 side chain. An example of the earlier bisphosphonates 
is etidronate, which was the ﬁ  rst bisphosphonate to have 
received approval for clinical use more than 30 years ago. 
Second-generation bisphosphonates include pamidronate 
and alendronate, characterized by free amino groups in their 
side chains. More complex molecules, such as risedronate, 
ibandronate, and zoledronate, have later been developed as a 
result of medicinal chemistry approaches to enhance efﬁ  cacy 
and safety; in risedronate and zoledronate their nitrogen 
groups are contained within heterocyclic rings (see Table 1) 
(Russell 2007).
The structure of the R2 chain is important in determin-
ing the potency of individual bisphosphonates in biologic 
models, and this includes a potential role for the R2 side 
chain in modulating bone binding. The presence and posi-
tion of nitrogen within the structure of the later-generation 
bisphosphonates are directly related to their relative potency. 
The most recent bisphosphonates, risedronate, ibandronate, 
and zoledronate, are all highly potent compared with the ear-
lier bisphosphonates. The difference in potency is probably 
attributable to the fact that the most recent bisphosphonates 
all contain nitrogen groups within their R2 side chains, 
which inhibits farnesyl pyrophosphate (FPP) synthase, a 
key enzyme located at an important branch point along the 
mevalonate pathway, which is critical for the production 
of cholesterol and isoprenoid lipids (Luckman et al 1998; 
Kavanagh et al 2006a, b; Russell 2007). Some of these lipids 
(eg, FPP and geranylgeranyl pyrophosphate) are necessary 
for the prenylation of some GTPases (eg, Ras, Rho, and Rac) 
regulating osteoclast morphology and function, cytoskeletal 
arrangement, membrane rufﬂ  ing, lysosome trafﬁ  cking, and 
cell survival (Ridley and Hall 1992).
In a study examining the potency of several nitrogen-
containing bisphosphonates, a correlation has been found 
between the ability of bisphosphonates to inhibit FPP synthase 
in vitro and inhibit protein prenylation in cell-free extracts 
as well as in puriﬁ  ed osteoclasts in vitro, and the ability to 
inhibit bone resorption in vivo (Dunford et al 2001). The 
order of potency in inhibiting FPP synthase (zoledronate  
risedronate  ibandronate  alendronate) closely matched 
the order of antiresorptive potency (Russell 2007).
Although bisphosphonates act mostly through inhibition 
of protein prenylation, their ability to adsorb to bone mineral 
also contributes to their antiresorptive potency and duration 
of action. The binding afﬁ  nities of various bisphosphonates 
have been shown to vary according to differences in the 
R2 side chain (zoledronate  alendronate  ibandronate = 
risedronate) (Nancollas et al 2005).
Thus, there are several observed differences in the 
clinical proﬁ  le and efﬁ  cacy among the bisphosphonates that 
underlie signiﬁ  cant variation in their key pharmacologic 
Figure 1 Generic bisphosphonate structure with functional domains.Clinical Interventions in Aging 2008:3(2) 282
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characteristics. The binding affinity to hydroxyapatite 
determines attachment to bone and duration of effect, and 
the inhibition of FPP synthase determines antiresorptive 
potential. The relative potency of different bisphospho-
nates is related to these two factors. Together, these factors 
combine to contribute to the overall effect of these drugs. 
For example, risedronate is a high-potent inhibitor of FPP 
synthase, but does not bind to hydroxyapatite as strongly 
as alendronate or zoledronate does (Dunford et al 2001; 
Nancollas et al 2006; Russell 2007). Risedronate would be 
expected to exhibit a distinct pharmacologic proﬁ  le on bone, 
which affects remodeling processes, mineral properties, the 
persistence of action, and bone quality when compared with 
other bisphosphonates, such as alendronate and ibandronate 
(Russell 2007).
On the other hand, the unique pharmacologic proﬁ  le of 
zoledronate may explain why it is possible to achieve pro-
found and sustained suppression of bone resorption with a 
single, low dose of this compound. Zoledronate has a high 
binding afﬁ  nity for bone mineral (Nancollas et al 2006). This 
increases the amount of drug that binds to bone and is likely 
to minimize the amount of drug that diffuses from bone after 
binding. Zoledronate is one of the most potent inhibitors of 
FPP synthase (Dunford et al 2001). This ampliﬁ  es the anti-
resorptive potential of the drug and reduces the total amount 
of drug required in each dose (Russell 2007). Both aspects, 
the speciﬁ  c pharmacodynamic features of zoledronate as 
well as its once-yearly intravenous application resulting in 
improved “compliance”, might contribute to its apparent 
beneﬁ  cial anti-fracture efﬁ  cacy.
Pharmacokinetics
Bisphosphonates have common pharmacokinetic properties, 
including poor intestinal absorption, high afﬁ  nity for bone 
mineral, inhibitory effects on osteoclastic bone resorption, 
prolonged bone retention, and elimination in the urine 
(Fleisch 1997).
Intestinal absorption is low with 0.6%–3% of the 
orally given bisphosphonate and furthermore impaired 
by food – especially foods containing calcium – so oral 
bisphosphonates should be given when fasting, just with 
plain water. Especially calcium and magnesium salts impair 
intestinal absorption of oral bisphosphonates (Chapurlat and 
Delmas 2006). The patient should fast for at least 30 minutes 
(alendronate, risedronate) or even 60 minutes (ibandronate) 
after taking oral bisphosphonates. This, of course, does not 
apply to intravenous bisphosphonates that do not require any 
special speciﬁ  cations for their application.
The plasma protein binding is low, and plasma half-life 
time of bisphosphonates is short. Approximately 40%–60% 
of the dose is concentrated in the skeleton, depending on the 
rate of bone turnover and the type of bisphosphonate, and the 
remaining amount is excreted, unaltered, in the urine.
Bisphosphonates in general stay embedded in bone 
for a very long time. However, there are signiﬁ  cant dif-
ferences in their effective biologic half-life explained by 
the binding afﬁ  nity of these drugs. Bisphosphonates can 
be detected in body ﬂ  uids months after administration. 
Higher-afﬁ  nity bisphosphonates should be detectable for 
longer periods because of their greater capacity to recycle 
at the bone surface; for example, the terminal half-life of 
alendronate in humans has been estimated to be about 10 
years (Russell 2007).
The suppressive effect of bisphosphonates on bone 
resorption is delayed by at least 1–2 days, in contrast to the 
more rapid effect of calcitonin. Both the concentration of 
bisphosphonate present in bone mineral at any time and the 
total dose administered over a long period of time, seem 
to be important for the magnitude of the reduction in bone 
turnover (Lin et al 1992, 1993; Papapoulos 2001; Riis et al 
2001; Tankó et al 2003).
No serum metabolite of bisphosphonates has been 
described so far. Nitrogen-containing bisphosphonates seem 
to bind to plasma proteins, and some of them are eliminated 
by a renal tubular secretory mechanism (Lin et al 1992, 
1993). Drug inter-actions are limited to aminoglycoside 
Table 1 Structures of bisphosphonates, including nitrogen-containing 
bisphosphonates licensed for the treatment of postmenopausal 
osteoporosis (alendronate, ibandronate, risedronate, zoledronate)Clinical Interventions in Aging 2008:3(2) 283
Osteoporosis: improving bisphosphonate efﬁ  cacy
antibiotics, with which severe hypocalcaemia can occur 
(Pedersen-Bjergaard and Myhre 1991).
Anti-fracture efﬁ  cacy
The aim of pharmacologic interventions in osteoporosis is to 
reduce the risk of its complications – of vertebral and hip frac-
tures as well as all non-vertebral fractures. The gold standard 
for demonstration of anti-fracture efﬁ  cacy in osteoporosis 
trials is the primary, predetermined analysis of the intention to 
treat (ITT) population; this is highlighted by the requirement 
of fracture prevention efﬁ  cacy in trials of at least 3 years’ 
duration for registration of new therapies (FDA 1994; CPMP 
2001). The majority of these trials have focused on the pre-
vention of vertebral fracture, with assessment of efﬁ  cacy in 
the prevention of non-vertebral fracture relying largely on 
the analysis of subgroups. The use of subgroup analyses to 
demonstrate efﬁ  cacy of a new treatment is not in line with 
recognized scientiﬁ  c standards and should be interpreted 
with caution. Indeed, the guidelines from the International 
Conference on Harmonization (ICH) of Technical Require-
ments for Registration of Pharmaceuticals for Human Use 
(EMEA 1998) explicitly state that such analyses should be 
used in an exploratory manner only and that conclusions as 
to the efﬁ  cacy of a treatment should not be based on such 
analyses alone (Boonen et al 2005).
Oral alendronate and risedronate have been used in the 
treatment of postmenopausal osteoporosis for many years, 
with a daily dosage regimen. Later, they came to be mar-
keted with weekly dosage regimens. Ibandronate is now 
available for use in an oral monthly dosage regimen and 
in an intravenous quarterly injection. All the approvals for 
non-daily and/or non-oral regimens of alendronate, risedro-
nate, and ibandronate have been based on results of so-called 
bridging studies only.
Most recently, zoledronate, with the once-yearly intrave-
nous application (15 minutes’ infusion), was licensed for the 
treatment of postmenopausal osteoporosis. The anti-fracture 
efﬁ  cacy of these four nitrogen-containing bisphosphonates 
is summarized in Table 2 (vertebral fractures) and Table 3 
(non-vertebral fractures).
All these agents have documented efﬁ  cacy in reducing 
the risk of vertebral fractures. Based on this proven risk 
reduction, bisphosphonates are the drug treatment of ﬁ  rst 
choice in postmenopausal osteoporosis in most countries 
worldwide.
The anti-fracture efﬁ  cacy has been established in large 
outcome trials of 3–4 years’ duration, but long-term fracture 
data in major study populations are missing. Some patients 
in the initial phase III trials were followed up subsequently, 
and the data of 10 years of treatment with alendronate in the 
FLEX study (Black et al 2006), as well as 7 years’ data with 
risedronate (Mellström et al 2004), showed a continuous 
increase in lumbar spine and total hip BMD.
In the FLEX study (n = 1099), women who discontin-
ued alendronate after 5 years showed a moderate decline 
in BMD and a gradual rise in biochemical markers but no 
higher fracture risk, other than for clinical vertebral frac-
tures, compared with those who continued alendronate. The 
authors concluded from these results that, for many women, 
discontinuation of alendronate for up to 5 years did not appear 
Table 2 Vertebral fracture incidence by treatment (ITT populations in fracture outcome studies of 3 years)
Drug  Authors  Fracture incidence (%)  Treatment effect  p value
Trial (total n)    placebo  active  RR (95% CI) 
Alendronate
FIT VFA (2,027)  Black et al 1996  15.0  8.0  0.53 (0.41, 0.68)  0.001
FIT CFA (4,432)*  Cummings et al 1998  3.8  2.1  0.56 (0.39, 0.80)  0.002
Risedronate        
VERT-NA (2,458)  Harris et al 1999  16.3  11.3+  0.59 (0.42, 0.82)  0.003
VERT-MN (1,226)  Reginster et al 2000  29.0  18.1+  0.51 (0.36, 0.73)  0.001
Ibandronate        
BONE (2,946)  Chesnut et al 2004  9.6  4.7#  0.38 (0.25, 0.59)  0.0001
Zoledronate
HORIZON-PFT (7,765)  Black et al 2007  10.9  3.3  0.30 (0.24, 0.38)  0.001
RR (95% CI) = relative risk and 95% conﬁ  dence interval. RR (95% CI) for ibandronate was estimated.
*FIT CFA trial duration was 4 years.
+Fracture incidence quoted for risedronate reﬂ  ects the 5 mg daily group only.
#Fracture incidence quoted for ibandronate reﬂ  ects the 2.5 mg daily group only.Clinical Interventions in Aging 2008:3(2) 284
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to signiﬁ  cantly increase fracture risk. However, women at 
very high risk of clinical vertebral fractures may beneﬁ  t by 
continuing beyond 5 years (Black et al 2006).
In the 6–7 years extension (n = 164) to 3 years vertebral 
fracture study, annualized incidence of new vertebral frac-
tures did not change in the 7-year risedronate group during 
the 6–7 years compared with 4–5 years, while a signiﬁ  cant 
reduction was observed in the placebo group that switched 
to risedronate treatment during years 6–7 (Mellström et al 
2004). Nevertheless, a lower scientiﬁ  c value of the latter 
studies must be considered. Other extension studies with 
ibandronate and zoledronate are ongoing and their data 
should be available shortly.
The anti-fracture efﬁ  cacy of most nitrogen-containing 
bisphosphonates available for postmenopausal osteoporosis, 
namely alendronate, risedronate, and ibandronate, was estab-
lished in trials on daily oral dosage regimens and in case of 
ibandronate with an intermittent, but not licensed oral regi-
men (20 mg every other day for the ﬁ  rst 24 days, followed 
by 9 weeks without treatment). Weekly oral dosage regimens 
with alendronate 70 mg (Rizzoli et al 2002) and risedronate 
35 mg (Brown et al 2002), monthly oral ibandronate 150 mg 
(Reginster et al 2006), and intravenous ibandronate 3 mg 
every 3 months (Delmas et al 2006), respectively, have been 
shown in non-inferiority studies to result at least in not sig-
niﬁ  cantly different, or even higher increases in lumbar spine, 
femoral neck, or hip BMD compared with the proven oral 
daily regimens. These bridging studies are aimed at show-
ing that a new regimen is at least as effective as a reference 
regimen (non-inferiority) with the same compound through 
the use of a surrogate marker, usually BMD. One- or 2-year 
duration for bridging studies can be accepted for a given 
compound, provided there is sufﬁ  cient evidence to support 
a good correlation between early changes in the chosen sur-
rogate endpoint (eg, BMD or biochemical markers changes) 
and long-term (up to 3 years) fracture risk reduction. However, 
safety studies with longer duration may be needed (Reginster 
et al 2006). In general, bridging studies cannot provide evi-
dence on the same level as original study protocols on fracture 
risk (limited patient number and duration).
In fact, zoledronate, with its licensed intravenous dosage 
of 5 mg once yearly, is the only compound that has directly 
been investigated for fracture outcomes in a study using 
non-daily administration.
For non-spine fracture, even in trials assessing them as a 
primary endpoint, differences in study design, randomized 
population, and varying deﬁ  nitions of what constitutes a 
non-vertebral fracture can inﬂ  uence outcomes. In addition, 
falls and fall-related risk factors have never been controlled 
for in or between individual studies (Miller 2008). Only rise-
dronate and zoledronate have been proven to reduce the risk 
of non-vertebral fractures in general, and of hip fractures in 
particular, in the ITT populations from randomized trials of 
at least 3 years’ duration. Furthermore, both risedronate and 
very recently also zoledronate have been shown to provide 
non-vertebral anti-fracture efﬁ  cacy in more than one study 
(RIS: Harris et al 1999; McClung et al 2001; ZOL: Black 
et al 2007; Lyles et al 2007).
Table 3 Non-vertebral fracture incidence by treatment (ITT populations in fracture outcome studies of 3 years) (Modiﬁ  ed and 
supplemented after Boonen et al 2005)
Drug  Authors  Fracture incidence (%)  Treatment effect  p value
Trial (total n)    placebo  active  RR (95% CI) 
Alendronate        
FIT VFA (2,027)  Black et al 1996  14.7  11.9  0.80 (0.63, 1.01)  0.063
FIT CFA (4,432) *  Cummings et al 1998  13.3  11.8  0.88 (0.74, 1.04)  0.130
Risedronate        
VERT-NA (2,458)  Harris et al 1999  8.4  5.2+  0.60 (0.39, 0.94)  0.020
VERT-MN (1,226)  Reginster et al 2000  16.0  10.9+  0.67 (0.44, 1.04)  0.063
HIP (9,331)  McClung et al 2001  11.2  9.4  0.80 (0.70, 1.00)  0.030
Ibandronate        
BONE (2,946)  Chesnut III et al 2004  8.2  9.1#  1.11 (0.83, 1.48)  not available
Zoledronate        
HORIZON-PFT (7,765)  Black et al 2007  10.7  8.0  0.75 (0.64, 0.87)  0.001
RR (95% CI) = relative risk and 95% conﬁ  dence interval. RR (95% CI) for ibandronate is estimated.
*FIT CFA trial duration was 4 years.
+Fracture incidence quoted for risedronate reﬂ  ects the 5 mg daily group only.
#Fracture incidence quoted for ibandronate reﬂ  ects the 2.5 mg daily group only.Clinical Interventions in Aging 2008:3(2) 285
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Additionally, meta-analyses of alendronate, as well as 
those of risedronate, have shown evidence of being efﬁ  cacious 
in preventing non-vertebral fracture (Boonen et al 2005). The 
use of data only from ITT populations in this meta-analysis, 
while likely to result in conservative estimates of the overall 
reduction in relative risk of fracture, ultimately gives the most 
reliable overall estimate of treatment efﬁ  cacy.
Otherwise, the only evidence for the non-vertebral 
anti-fracture efﬁ  cacy of ibandronate so far is a post-hoc 
subgroup analysis from the BONE study suggesting that 
non-vertebral fracture risk might be reduced in patients with 
the lowest baseline BMD at the femoral neck with a T score 
below –3.0 SD (Chesnut et al 2004).
Although a direct comparison of one bisphosphonate with 
another cannot be made in the absence of head-to-head stud-
ies of fracture outcome, the magnitude of effect with zoledro-
nate (fracture risk reduction for vertebral, non-vertebral and 
hip fractures of 75%, 25% and 40% respectively) appears to 
be at least similar to, and possibly better than, that reported 
for other interventions (Compston 2007). Most robust data 
exist with zoledronate in intravenous dosage regimens, and 
with risedronate in oral dosage regimens.
Many comparative studies have investigated the effect 
magnitudes of different bisphosphonates on bone markers and 
bone mineral density, eg, the FACT study comparing alendro-
nate and risedronate efﬁ  cacy on such a basis (Reid et al 2006). 
These trials might offer additional information, but they have 
not been able to make up for the lack of comparative outcome 
studies on fracture incidence. Therefore, the authors will not 
reﬂ  ect on these surrogate parameter studies, since there is no 
evidence for a sufﬁ  cient correlation between bone marker 
reduction and BMD increase on the one hand, and the overall 
fracture reduction among the different bisphosphonates on the 
other hand. The same applies to studies using observational 
data derived from commercially available datasets to com-
pare fracture risk reduction of different bisphosphonates, eg, 
the REAL study comparing the reduction of early fracture 
risk of alendronate vs risedronate treatment (Silverman et al 
2007). The conclusion that risedronate is more effective than 
alendronate, however, has limited justiﬁ  cation. Although 
prospective, observational studies often provide preliminary 
data about the effectiveness of certain therapies, randomized 
placebo-controlled trials remain the gold standard for evaluat-
ing drug efﬁ  cacy (Black and Rosen 2007).
Health-related quality of life
Over the last 30 years, health-related quality of life (HR-
QOL) has emerged as an important attribute of clinical 
investigation and patient care, and is now a key component 
of what has recently come to be known as “patient-reported 
outcomes”. Given the impact of incident vertebral and/or hip 
fractures on HR-QOL, it might be expected that a therapy 
reducing the incidence of such fractures would result in a 
relatively better quality of life (McCloskey 2006). Otherwise, 
a recent review of utility values for osteoporotic fractures to 
be used in economic analyses has highlighted the remarkably 
few studies on the impact of osteoporotic fractures (Brazier 
et al 2002).
Until today, studies showing a direct effect of an anti-
osteoporotic treatment, including nitrogen-containing 
bisphosphonates, on HR-QOL have been very rare. 
Statistical power is inadequate to demonstrate effects on 
HR-QOL in the majority of pivotal studies, which are 
usually designed to show a reduction in vertebral fracture 
risk (McCloskey 2006).
In the Fracture Intervention Trial (FIT) of alendronate 
in 2027 postmenopausal women aged 55 to 81 years with 
low femoral neck bone density and a preexisting vertebral 
fracture, alendronate therapy for 3 years reduced the number 
of days of bed disability and the number of days of limited 
activity caused by back pain (Nevitt et al 2000). Irrespective 
of the treatment assignment, women with new clinically 
recognized vertebral fractures during follow-up experienced 
a higher risk in terms of the number of days of bed disability 
and of limited activity because of back pain after the frac-
ture. Women receiving alendronate reported an average of 
3.2 fewer days of bed rest (p = 0.001) and 11.4 fewer days 
of limited activity (not including days of bed rest) because 
of back pain (p = 0.04) during follow-up than those receiv-
ing placebo. In the alendronate group, relative to the placebo 
group, there was a reduced risk of 1 or more bed-rest days 
(relative risk 0.68; 95% conﬁ  dence interval [CI] 0.53–0.87), 
of 7 or more bed-rest days (0.44; 0.30–0.64), and of 7 or more 
limited-activity days (0.87; 0.76–0.99).
In an actual review on ibandronate and other bisphos-
phonates, the authors conclude that ibandronate offers an 
effective and convenient choice for the relief of bone pain 
in a variety of diseases with increased bone turnover (Ringe 
and Body 2007). This has widely been proven for malig-
nant conditions, but, in contrast, there are only very limited 
data available on pain relief in non-malignant conditions 
as corticosteroid-induced osteoporosis, localized transient 
osteoporosis (bone marrow edema) and sternocostoclavicular 
hyperostosis.
Data for HR-QOL and mortality have been published 
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with zoledronate, the Pivotal Fracture Trial (PFT) (Black 
et al 2007) and the Recurrent Fracture Trial (RFT) (Lyles 
et al 2007). In the HORIZON-PFT, 3889 postmenopausal 
women (mean age, 73 years) were randomly assigned to 
receive a single 15-minute infusion of zoledronate (5 mg) 
and 3876 were assigned to receive placebo at baseline, at 
12 months, and at 24 months; the patients were monitored for 
36 months. The once-yearly infusion of zoledronate during a 
3-year period signiﬁ  cantly reduced the risk of vertebral, hip, 
and other fractures. In an interim analysis in 2005, the authors 
reported also fewer days of limited activity due to back pain 
or fractures in zoledronate patients compared to placebo: 
61 vs 72 days (p = 0.0076), and 6 vs 10 days (p = 0.001), 
respectively (Black et al 2006).
Reduction of mortality (zoledronate)
The only study so far demonstrating improved survival in 
treated osteoporosis patients is the HORIZON-RFT with 
zoledronate (Lyles et al 2007). In this randomized, double-
blind, placebo-controlled trial in men and women after hip 
fracture, 1065 patients were assigned to receive yearly intra-
venous zoledronate (at a dose of 5 mg), and 1062 patients 
were assigned to receive placebo. The infusions were ﬁ  rst 
administered within 90 days after surgery for a hip fracture. 
In this event-driven study (new clinical fractures), the median 
follow-up was 1.9 years. The rates of any new clinical fracture 
were 8.6% in the zoledronate group and 13.9% in the placebo 
group, a 35% risk reduction with zoledronate (p = 0.001); 
the respective rates of a new clinical vertebral fracture were 
1.7% and 3.8% (p = 0.02), and the respective rates of new 
non-vertebral fractures were 7.6% and 10.7% (p = 0.03). In 
the safety analysis, 101 of 1054 patients in the zoledronate 
group (9.6%) and 141 of 1057 patients in the placebo group 
(13.3%) died, a reduction of 28% in deaths from any cause 
in the zoledronate group (p = 0.01) (see Figure 2).
Safety
General safety
Evidence supports a good safety proﬁ  le for nitrogen-containing 
bisphosphonates in postmenopausal osteoporosis. Neverthe-
less, some tolerability issues have been associated with their 
use. Upper gastrointestinal (UGIT) adverse events (AEs) in 
oral bisphosphonates, renal toxicity, inﬂ  uenza-like illness, and 
osteonecrosis of the jaw, uveitis, and also atrial ﬁ  brillation have 
been reported and should be considered. Strampel et al (2007) 
provided recently an overview of the safety issues associated 
with the nitrogen-containing bisphosphonates and discussed 
the potential effect of these issues on adherence.
In clinical trials, UGIT AEs, including severe events 
such as esophageal ulcer, esophagitis, and erosive esopha-
gitis, have been reported at similar frequencies in placebo- 
and active-treatment arms. In a randomized, head-to-head 
comparison of alendronate and risedronate, the overall 
incidence of clinical AEs was similar for both compounds 
(Rosen et al 2005). However, post-marketing studies have 
highlighted UGIT AEs as a concern. These studies show 
that a signiﬁ  cant portion of patients is less compliant with 
administration instructions outside strict clinical trial supervi-
sion, and when oral bisphosphonates are not administered as 
directed, patients are more likely to experience UGIT AEs. 
Some clinical trials with oral bisphosphonates have sug-
gested that a decrease in the frequency of administration may 
lead to improvement in gastrointestinal tolerability. UGIT 
intolerability can be minimized by explaining to the patient 
and/or caregiver the importance of following administration 
instructions (Strampel et al 2007).
With intravenous bisphosphonate application, venous 
irritation or thrombophlebitis might be encountered. Intra-
venous bisphosphonates offer an alternative regimen for 
patients with osteoporosis. Modern nitrogen-containing IV 
bisphosphonates (ie, ibandronate, zoledronate) have also 
shown a better safety proﬁ  le in relation to renal toxicity 
(Chang et al 2003; Delmas et al 2006; Black et al 2007; 
Lyles et al 2007) compared with earlier substances (eg, eti-
dronate, clodronate) (Bounameaux et al 1983). AEs on renal 
function with dosages used for postmenopausal osteoporosis 
are generally rare and primarily related to infusion rate and 
dose. Due to lack of data, no conclusions can be made about 
bisphosphonate safety in patients with intrinsic renal disease 
or an estimated glomerular ﬁ  ltration rate of 30 mL/min 
(Lewiecki and Miller 2007).
Inﬂ  uenza-like illness, often referred to as an acute-phase 
reaction, covers symptoms such as fatigue, fever, chills, 
myalgia, and arthralgia. These symptoms are transitory 
and self-limiting and usually do not recur after subsequent 
drug administration (Strampel et al 2007). Symptoms of 
inﬂ  uenza-like illness have been associated with both IV and 
oral bisphosphonates (Delmas et al 2006; Black et al 2007; 
Bock et al 2007).
In the HORIZON-PFT with zoledronate, the number of 
patients who had arrhythmia in the zoledronic-acid group 
(266 patients, or 6.9%) was signiﬁ  cantly higher than that in 
the placebo group (203 patients, or 5.3%; p = 0.003). Seri-
ous atrial ﬁ  brillation, as a subcategory of all arrhythmias, 
was more common among patients in the zoledronic acid 
group. Otherwise, there was no difference in arrhythmia Clinical Interventions in Aging 2008:3(2) 287
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related complications (eg, strokes). Furthermore, no time 
relationship to the zoledronate infusion was observed. 
The events were uniformly distributed over time, with 
the vast majority of events occurring more than 30 days 
after infusion, by which time zoledronate was undetectable 
in the circulation (Black et al 2007). There is no further 
evidence for an increased risk of serious atrial ﬁ  brilla-
tion with zoledronate, neither from other clinical trials 
in malignant conditions or osteoporosis – rather to the 
contrary (Lyles et al 2007) – nor from the extensive post-
marketing experience in over 1.5 million tumor patients 
receiving 2–10 times higher dosages per year, compared 
with the once-yearly 5 mg dose used in postmenopausal 
osteoporosis. Nevertheless, in a letter to the editor, pub-
lished in the same issue of the New Engl J Med as the 
HORIZON-PFT data, Cummings et al (2007) reported 
on their observations on atrial ﬁ  brillation in the FIT with 
alendronate. The overall risk of atrial ﬁ  brillation AEs in 
FIT was similar between alendronate and placebo (2.5 vs 
2.2%; p = 0.42). Looking only at atrial ﬁ  brillation AEs that 
were serious, the incidence was numerically higher with 
alendronate (1.5 vs 1.0%; p = 0.07), but not statistically 
signiﬁ  cant (Cummings et al 2007). In general, there is no 
pharmacologic mechanism known and also no repeated 
evidence from clinical trials or post-marketing observation 
so far indicating a medical concern based on a possible 
causality between bisphosphonate use and increased risk 
for serious atrial ﬁ  brillation.
Bone safety
Osteonecrosis of the jaw (ONJ) has also been associated 
with nitrogen-containing bisphosphonates, particularly in 
tumor patients treated with high IV doses. A small number 
of patients with osteoporosis using oral bisphosphonates have 
also reported this AE. A multidisciplinary expert group of the 
American Society for Bone and Mineral Research (ASBMR) 
reviewed all pertinent published data on bisphosphonate-
associated ONJ as well as the Food and Drug Administra-
tion’s (FDA) drug adverse event reports. A case deﬁ  nition 
was developed so that subsequent studies could report on the 
same condition. The task force deﬁ  ned ONJ as the presence 
of exposed bone in the maxillofacial region that did not heal 
within 8 weeks after identiﬁ  cation by a health care provider. 
Based on review of both published and unpublished data, 
the risk of ONJ associated with oral bisphosphonate therapy 
for osteoporosis seems to be low, estimated at 1 in 10,000 
to 100,000 patient-treatment years. However, the task force 
recognized that information on incidence of ONJ is rapidly 
evolving and that the true incidence may be higher. The risk 
of ONJ in patients with cancer treated with high doses of 
intravenous bisphosphonates is clearly higher in the range 
of 1–10 per 100 patients (depending on duration of therapy) 
(Khosla et al 2007). These estimates are also supported by 
repeated interim analyses from the German central ONJ 
register (Felsenberg et al 2006).
Post-marketing experience with IV bisphosphonates in 
postmenopausal osteoporosis remains limited. There have 
been no data so far from clinical studies using IV ibandronate 
or zoledronate in this condition indicating any increased risk 
for ONJ, as observed in patients with malignant conditions. 
In the HORIZON-PFT with zoledronate, eg, there were no 
spontaneous reports of ONJ. From a research of the trial 
database of AEs, followed by expert adjudication, 2 cases of 
potential ONJ were identiﬁ  ed (1 in the placebo group, 1 in the 
zoledronic acid group). In both patients delayed healing fol-
lowed surgical manipulation and was subsequently resolved 
with antibiotic therapy and débridement (Black et al 2007).
Another aspect of bone safety in long-term bisphosphonate 
use has been discussed for several years. In general, slowed 
bone remodeling and an increased degree of mineralization are 
presumed to result in an improved bone quality, with greater 
bone strength as a consequence (Chapurlat and Delmas 2006). 
Prolonged use of bisphosphonates at high doses might be 
associated, however, with the accumulation of micro-cracks. 
Indeed, in Beagle dogs receiving risedronate (5 mg/kg body 
weight daily) or alendronate (10 mg/kg body weight daily) 
for 1 year, micro-damage accumulation has been described by 
Figure 2 Mortality as a secondary endpoint in the HORIZON-RFT (Recurrent 
Fracture Trial) with zoledronate: in the safety analysis, a total of 242 of 2111 patients 
(11.5%) died during the study, 101 of 1054 (9.6%) were in the zoledronate group and 
141 of 1057 (13.3%) were in the placebo group (hazard ratio for the zoledronate 
group, 0.72; 95% CI, 0.56–0.93; p = 0.01). Adapted with permission from Lyles KW, 
Colón-Emeric CS, Magaziner JS, et al. 2007. Zoledronic acid and clinical fractures and 
mortality after hip fracture. N Engl J Med, 357:1799–809. Copyright © 2007 Mas-
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David Burr’s group in ribs (Mashiba et al 2005) and vertebrae 
(Mashiba et al 2001). Simultaneously, trabecular bone volume 
and vertebral strength increased signiﬁ  cantly, while toughness 
tended to be reduced. Micro-damage accumulation was also 
shown in the vertebrae of Beagle dogs receiving a high dose of 
incadronate, while vertebral strength improved and vertebral 
toughness was reduced (Komatsubara et al 2003). The clinical 
signiﬁ  cance of these ﬁ  ndings, however, remains unclear since 
the doses of bisphosphonates used in these animal studies 
were about 6-fold greater than those used in the treatment of 
humans, and some parameters of bone quality were improved, 
while others tended to deteriorate slightly (Chapurlat and 
Delmas 2006). Another study examined the occurrence of 
micro-cracks in the bones of Beagle dogs receiving risedronate 
or alendronate at doses comparable to those used in humans 
for the treatment of osteoporosis. These results indicated an 
increased micro-damage accumulation, but without signiﬁ  cant 
negative effects on the mechanical properties of bone (Allen 
et al 2005). Otherwise, the authors showed very recently 
that neither risedronate nor alendronate treatment in Beagle 
dogs altered the strength–density relationship compared with 
vehicle, suggesting that increases in vertebral strength with 
bisphosphonate treatment are explained by increased density. 
The energy absorption–density relationship was altered by 
alendronate, resulting in signiﬁ  cantly lower energy absorp-
tion capacity at a given areal bone mineral density (aBMD) 
compared with both vehicle (–22%) and risedronate (–14%). 
In accordance with the stated conclusions, these data docu-
ment that after adjusting for increased aBMD, vertebrae from 
animals treated with bisphosphonates have similar strength as 
those from untreated animals. Conversely, when adjusted for 
increased aBMD, alendronate treatment, but not risedronate 
treatment, signiﬁ  cantly reduces the energy required for verte-
bral fracture and is indicative of an alteration in bone quality 
(Allen and Burr 2008).
However, as no obvious mineralization defect was 
observed in bone biopsies collected from women who had 
received alendronate for 10 years in the FLEX trial with 
alendronate in postmenopausal women (Recker et al 2004), 
despite their markedly suppressed bone turnover, there is 
currently no evidence of substantial bone safety concern of 
bisphosphonates administered in the long term (Chapurlat 
and Delmas 2006).
Bisphosphonates in clinical practice
The problem of non-adherence
International treatment guidelines recommend the use of 
bisphosphonates as ﬁ  rst-line therapy due to their proven 
efﬁ  cacy in fracture risk reduction and overall beneﬁ  cial 
safety proﬁ  le. Achievement of optimal treatment results 
in individual patients requires a long-term treatment 
with these substances for at least 3–5 years. Otherwise, 
the effectiveness of treatments for chronic conditions is 
compromised by suboptimal adherence, compliance and 
persistence with treatment in general, and in asymptomatic 
diseases, in particular (Christensen et al 1997; Miller 1997; 
Benner et al 2002).
Compliance describes the quality of intake of a given 
medication and considers the extent to which a dosing regi-
men and its associated instructions are followed. Compli-
ance can often be quantiﬁ  ed by a surrogate measure, the 
medication-possession ratio (MPR), which is the number of 
days of available medication divided by the number of days 
of study follow-up. Persistence describes the length of time 
patients continue to take their medication, and is deﬁ  ned 
as the time from treatment initiation to treatment comple-
tion/discontinuation. Adherence is a summary term that is 
determined by compliance and persistence of medication 
intake and describes the extent and the quality of medication 
intake (see Figures 3 and 4) (Badamgarav and Fitzpatrick 
2006; Payer et al 2007). Adherence to medication in post-
menopausal osteoporosis is in line with the general ﬁ  nding 
of low persistence rates in other chronic diseases (Reginster 
and Rabenda 2006).
A number of studies (Papaioannou et al 2003; Segal et al 
2003; Yood et al 2003; Caro et al 2004) have reported poor 
levels of compliance and persistence with commonly used 
drug therapies for osteoporosis including bisphosphonates 
(Cramer et al 2007).
Approximately half of all patients do not take oral 
bisphosphonates regularly (Lombas et al 2001) or con-
tinue with treatment (McCombs et al 2004) for at least 
12 months, with many discontinuing soon after initiation 
(Weycker et al 2006). While less frequent dosing regimens 
have signiﬁ  cantly improved compliance and persistence, 
adherence to treatment remains suboptimal (Brankin et al 
2006; Cramer et al 2006) and is likely to be compromising 
the beneﬁ  ts of reduced fracture risk demonstrated in clinical 
trials (Adachi et al 2007).
Based on several reviews, the World Health Organization 
estimated that long-term adherence in chronic disease aver-
ages only 50% (WHO 2003b). It seems that this is particu-
larly true for diseases such as postmenopausal osteoporosis 
that have few or no clinical symptoms, as the patient does 
not experience ill effects from the disease or the subsequent 
beneﬁ  t from treatment. In the treatment of osteoporosis, Clinical Interventions in Aging 2008:3(2) 289
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non-adherence to bisphosphonate therapy negatively impacts 
upon treatment outcomes (Reginster and Rabenda 2006). 
First of all, a poor adherence results in a signiﬁ  cantly higher 
rate of vertebral and non-vertebral fractures, compared with 
that observed in adherent patients, and is associated with 
a decreased quality of life (Caro et al 2004; Sebaldt et al 
2004; Harris et al 2005; Siris et al 2006). Non-adherence to 
bisphosphonates also increases the risk of hospitalization 
associated with osteoporotic fractures (Goettsch et al 2005) 
and the incidence of secondary complications associated 
with fractures, such as pain, nosocomial infections, and 
pulmonary thromboembolism, leading to higher healthcare 
costs (Reginster and Rabenda 2006).
In order to characterize the relationships between 
adherence (compliance and persistence) to bisphosphonate 
therapy and risk of speciﬁ  c fracture types in postmenopausal 
women, Siris et al (2006) collected data from 2 claims 
databases in the US during a 5-year period. Claims from 
35,537 women (age, 45 years) receiving an alendronate or 
risedronate prescription were evaluated for 6 months before 
the index prescription and during 24 months of follow-up 
to determine osteoporotic fractures, persistence (no gap in 
reﬁ  lls for 30 days during 24 months), and reﬁ  ll compliance 
(MPR  0.80). Only 43% were reﬁ  ll compliant, and 20% 
persisted with bisphosphonate therapy during the 24-month 
study period. Total, vertebral, non-vertebral, and hip fractures 
were signiﬁ  cantly lower in reﬁ  ll-compliant and persistent 
patients, with relative risk reductions of 20%–45%. There 
was a progressive relationship between reﬁ  ll compliance and 
fracture risk reduction, commencing at reﬁ  ll compliance rates 
of approximately 50% and becoming more pronounced at 
compliance rates of 75% and higher (see Figure 5).
Penning-van Beest et al (2007) analyzed 8822 new female 
users (age, 45 years) of alendronate or risedronate with a total 
of 22,484 person-years of follow-up. Patients were identiﬁ  ed 
from the PHARMO Record Linkage System (PHARMO-RLS) 
of the Netherlands, including drug-dispensing and hospitaliza-
tion data of about 2 million residents, and were followed until 
ﬁ  rst hospitalization for an osteoporotic fracture, death, or end 
of study period. Compliance with bisphosphonates during 
follow-up was measured over 90-day intervals using MPR. 
Non-compliant bisphosphonate use was associated with a 45% 
increased fracture risk compared to compliant use (MPR  80%). 
Classifying compliance into 5 categories, fracture risk gradually 




Figure 3 Adherence and its components. Adapted with permission from Payer J, 
Killinger Z, Sulková I, Celec P. 2007. Therapeutic adherence to bisphosphonates. Biomed 
Pharmacother, 61:191–3. Copyright © 2007 Elsevier.
Figure 4 Persistence refers to the duration of time during which a medication is taken. Compliance is the proportion of medication taken at a given time according to 
instructions while persistent. Adherence represents compliance over time and can be estimated within discrete periods using the medication possession ratio. Reproduced 
with permission from Badamgarav E, Fitzpatrick LA. 2006. A new look at osteoporosis outcomes: the inﬂ  uence of treatment, compliance, persistence, and adherence. Mayo Clin 
Proc, 81:1009–12. Copyright © 2006 Mayo Foundation for Medical Education and Research. All rights reserved.Clinical Interventions in Aging 2008:3(2) 290
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MPR 20% was associated with an 80% increased fracture risk 
compared with a MPR 90%.
A retrospective cohort study of 17,988 new alendronate 
or risedronate users (age, 40 years) analyzed pharmacy and 
medical claims data from 45 large US employers (Briesacher 
et al 2007). After 1–3 years of follow-up, only 30.6%–42.9% 
of patients could achieve high compliance (80%–100%), 
17.4%–23.0% moderate compliance (79%–40%), and 
33.8%–52.0% had low compliance (0%–39%). Multivariate 
models of fracture risk showed beneﬁ  ts with compliance 
levels of at least 60%. Indicated health care costs were sig-
niﬁ  cantly lower (p  0.05) in high to moderate compliant 
patients with total costs savings of US$859–US$366 per 
year. Although reductions in fracture risk could be detected 
in individuals achieving as little as 60% compliance with 
bisphosphonates, as many as 34% of patients in the ﬁ  rst year 
of therapy and 52% by the third year did not reach even these 
minimal compliance levels required to receive beneﬁ  ts.
Another recent study was performed in Belgium to 
investigate adherence to bisphosphonate therapy and its 
speciﬁ  c impact on the risk of hip fracture using the Belgian 
national social security database (Rabenda et al 2007). 
Patients enrolled in the study were postmenopausal women, 
naïve to bisphosphonates, who received ﬁ  rst prescription 
of alendronate. After 12 months, the rate of persistence 
was 39.45%. For each decrease of the MPR by 1%, the 
risk of hip fracture increased by 0.4% (odds ratio 0.996; 
95% CI 0.994–0.998; p  0.001). The relative risk reduc-
tion for hip fractures was 60% (hazard ratio 0.404; 95% CI 
0.357–0.457; p  0.0001) for persistent, compared with non-
persistent, patients. Although mean MPR, as a measure of 
compliance, at 12 months proved signiﬁ  cantly higher among 
patients receiving weekly (n = 15.021), in contrast to daily 
alendronate (n = 14,136) (daily = 58.6%; weekly = 70.5%; 
p  0.001), it remained suboptimal.
All these results conﬁ  rm a statistically signiﬁ  cant asso-
ciation between the level of adherence with daily or weekly 
oral bisphosphonates and the level of fracture risk, emphasiz-
ing the need to optimize treatment adherence for obtaining 
maximal treatment beneﬁ  t.
Improvement of adherence
In order to improve therapeutic adherence it is important 
to know why patients stop taking, or do not take, adequate 
amounts of their medication.
A survey carried out for the International Osteoporosis 
Foundation (IOF) by IPSOS Health in 2005 aimed to under-
stand the reasons why women with osteoporosis do not stay 
on treatment. It showed that 34% of women interviewed 
either did not know what the beneﬁ  ts of their medication were 
or wrongly thought there were no beneﬁ  ts at all. As patients 
often have no symptoms until they suffer a fracture, they do 
not feel that treatment is worth taking or do not believe they 
have a disease that needs treatment. This means they may 
consider the pill burden and the inconvenience of the dosing 
requirements to be unnecessary. Drawbacks of treatment 
identiﬁ  ed by women were predominantly related to inconve-
nience and side effects (IOF 2005) (see Figure 6).
Patients ﬁ  nd the strict dosing instructions for bisphos-
phonates difﬁ  cult to follow; fasting (overnight for at least 
6 hours prior to taking the medication and 30–60 minutes after 
administration) and posture requirements (staying upright for 
30–60 minutes after taking the medication) can be inconvenient 
and often not feasible in the daily routine. The strict require-
ments interfere not only with eating and drinking, but also 
with taking other medications, especially if these need to be 
taken with food. Despite clinical studies reporting side-effect 
proﬁ  les that are similar to placebo, many patients stop taking 
oral bisphosphonates due to AEs (McHorney et al 2007). The 
main complaints with oral bisphosphonates are UGIT irrita-
tion, dyspepsia, nausea, upper abdominal pain, vomiting, and 
gastroesophageal reﬂ  ux (Reginster and Rabenda 2006).
Dosing frequency
It is acknowledged for the oral bisphosphonates that most of 
the above-mentioned attributes cannot be altered. However, 
one attribute that can be changed is the dosing frequency. 
Figure 5 Probability of fracture in 24 months in the bisphosphonate-treated patients. 
Reproduced with permission from Siris ES, Harris ST, Rosen CJ, et al. 2006. Adherence 
to bisphosphonate therapy and fracture rates in osteoporotic women: relationship 
to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc, 
81:1013–22. Copyright © 2006 Mayo Foundation for Medical Education and Research. 
All rights reserved.
Abbreviation: MPR, medication possession ratio.Clinical Interventions in Aging 2008:3(2) 291
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Several studies have evaluated patient preferences for dif-
ferent dosing schedules and the impact such ﬁ  ndings have 
had on therapeutic adherence. A systematic review on patient 
preference in the management of postmenopausal osteoporo-
sis with (oral) bisphosphonates has recently been published 
in this journal (Reginster and Rabenda 2006).
Weekly regimens of oral alendronate and risedronate are 
both licensed and are widely accepted as being at least as 
effective as the daily regimens with the added convenience of 
only 1 tablet a week. In several studies evaluating bisphospho-
nate regimen preference with alendronate or risedronate, there 
was a strong preference for a weekly regimen vs daily dosing 
(Simon et al 2002; Baroutsou et al 2004; Cramer et al 2004; 
Kendler et al 2004; Recker et al 2004; Bartl et al 2006).
Meanwhile, improved compliance, expressed in higher 
MPR and/or persistence in patients treated with weekly oral 
bisphosphonates compared to those on daily treatment, is 
reported consistently in numerous studies (most recently: 
Recker et al 2004; Cramer et al 2005; Bartl et al 2006; Siris et al 
2006; Penning-van Beest et al 2007; Rabenda et al 2007).
Cramer et al (2007) reviewed 14 reports, which described 
14 databases. The overall percentage of patients persist-
ing with therapy for 1 year ranged from 17.9% to 78.0%. 
Compliance, assessed as mean MPR, ranged from 0.59 to 
0.81. When comparing compliance with weekly and daily 
bisphosphonates, the mean MPR was consistently higher for 
weekly vs daily therapy (0.58–0.76 vs 0.46–0.64 for patients 
receiving weekly and daily bisphosphonate therapy, respec-
tively). Persistence was also improved in patients receiving 
weekly bisphosphonates, assessed by both length of persis-
tence (194–269 days [weekly] and 134–208 days [daily]) and 
percentage of persistent patients at the end of the follow-up 
period (35.7%–69.7% [weekly] and 26.1%–55.7% [daily]). 
However, although patients using weekly bisphosphonate 
medication follow their prescribed dosing regimens better 
than those using daily therapy, overall compliance and per-
sistence rates were suboptimal.
Ibandronate makes possible a further increase in dos-
ing interval. It is the ﬁ  rst and only nitrogen-containing oral 
bisphosphonate so far licensed for osteoporosis in a monthly 
regimen, and it is anticipated that this regimen may have a 
positive impact on adherence.
Two clinical studies using patient surveys have demon-
strated a strong patient preference for a monthly vs a weekly 
oral bisphosphonate regimen (Emkey et al 2005; Hadji et al 
2007). The BALTO (Bonviva ALendronate Trial in Osteo-
porosis) studies evaluated patients’ preference for monthly 
oral ibandronate or weekly oral alendronate. BALTO I 
(Emkey et al 2005) in the US only and BALTO II (Hadji 
et al 2007) in the US and Europe comprised 2 separate 
studies of identical design, conducted in all together 692 
bisphosphonate-naïve or bisphosphonate-lapsed women with 
postmenopausal osteoporosis. Patients were randomized to 
receive either monthly oral ibandronate for 3 months fol-
lowed by weekly oral alendronate for 12 weeks, or weekly 
oral alendronate for 12 weeks followed by monthly oral 
ibandronate for 3 months. Patient preference and opinions 
on convenience were assessed using a subject-completed 
questionnaire. In both studies of those women who expressed 
a preference (BALTO I: 92.6%, BALTO II: 93.1%), the 
majority (BALTO I: 71.4%, BALTO II: 70.6%) preferred 
the monthly ibandronate regimen to the weekly alendronate 
regimen (p  0.0001). Among the most common reasons 
for preferring the monthly ibandronate regimen, one can 
identify the ease of long-term adherence and better ﬁ  t to 
lifestyle. Patient preference for a medication may encourage 
therapeutic adherence, but further studies are needed to 
determine how well preference and convenience translate 
into prolonged adherence (Emkey et al 2006; Reginster and 
Rabenda 2006; Hadji et al 2007).
The UK PERsistence Study of Ibandronate vs alendro-
naTe (PERSIST) is the ﬁ  rst trial to investigate persistence 
within 6 months of a monthly bisphosphonate regimen vs a 
weekly bisphosphonate regimen. Patients were randomized 
to receive either a monthly ibandronate regimen (plus a 
patient support program) or a weekly alendronate regimen 
(Cooper et al 2006). The 6-month data show that, compared 
with alendronate, there was a 47% relative improvement in 
the proportion of patients persisting with treatment in the 
ibandronate/patient support program group. Nevertheless, 
it has to be stated clearly, that the patient support program 
Figure 6 IOF Survey 2005: Patient drawbacks associated with oral bisphosphonates. 
Some patients stated more than one drawback. (Derived from IOF 2005).
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was available to monthly ibandronate patients only, reﬂ  ecting 
current UK practice. It remains open, therefore, how much 
the data reﬂ  ect on different dosing regimens and on the effect 
of a patient support program, respectively.
In the Risedronate Claims Study from Taylor Nelson 
Sofres Healthcare’s online panel (Gold et al 2006), prefer-
ence data were collected for weekly vs monthly bisphospho-
nate therapy among 617 osteoporotic women (age 50 years) 
currently using bisphosphonates. In addition, the IMS lon-
gitudinal prescription database was used to evaluate adher-
ence among patients currently taking weekly risedronate or 
monthly ibandronate. More patients preferred weekly over 
monthly therapy (82% vs 18% respectively, p  0.0001) after 
receiving information about fracture efﬁ  cacy differences. 
Adherence was signiﬁ  cantly higher (p  0.0001) in patients 
taking weekly risedronate vs monthly ibandronate in all 
groups (72.7 ± 26.4% vs 52.8 ± 31.5%, overall sample; 
51.7 ± 31.3% vs 46.6 ± 30.7%, new to therapy; 53.0 ± 32.2% 
vs 46.6 ± 30.7%, post-market). Patients preferred a weekly 
dosing regimen with proven vertebral and non-vertebral 
fracture efﬁ  cacy. A monthly dosing regimen did not increase 
patient compliance and persistence with bisphosphonate 
therapy in this study.
Importantly, we do interpret the results of the rapidly 
growing number of studies in different treatment regimens 
with oral bisphosphonates. Patient compliance, persistence 
and adherence are complex and methods to increase adher-
ence beyond oral dosing schedules should be further inves-
tigated (Gold et al 2006).
In an actual US study with 3274 women (age, 45 years), 
who ﬁ  lled a prescription for an oral bisphosphonate in January 
or February of 2006 and were identiﬁ  ed through a dispensing 
database of 3300 retail pharmacies, multivariate analyses of 
their standardized telephone surveys showed that those most 
symptomatic in terms of side effects and those with the most 
skeptical beliefs in drug effectiveness and drug safety had 
odds ratios for non-adherence of 6.78 (95% CI 4.67–9.86), 
5.70 (95% CI 3.65–8.92), and 2.26 (95% CI 1.49–3.42), 
respectively. Osteoporosis health concerns, dosing frequency 
convenience as well as concerns regarding medication costs 
were not statistically associated with non-adherence to 
bisphosphonate therapy (McHorney et al 2007).
IV application
A recently available alternative to oral bisphosphonate treat-
ment is the IV application of bisphosphonates as ibandro-
nate or zoledronate. IV ibandronate 3 mg given quarterly is 
considered to be at least as effective as oral daily ibandronate 
2.5 mg (Delmas et al 2006), which has been shown to reduce 
the incidence of vertebral fractures in the BONE trial. A 
post-hoc analysis showed that ibandronate 2.5 mg daily 
reduced in addition the risk of non-vertebral fractures in a 
higher-risk subgroup (femoral neck BMD T score –3.0) 
(Chesnut III et al 2004). The results from the ITT analysis 
of the HORIZON-PFT indicated that zoledronate 5 mg 
once-yearly decreased signiﬁ  cantly the risk for all relevant 
osteoporotic fractures: morphometric and clinical vertebral 
fractures, non-vertebral and hip fractures as well as all clinical 
fractures, respectively.
In the HORIZON-Switch trial on safety and efﬁ  cacy of 
once-yearly IV zoledronate 5 mg vs weekly oral alendronate 
70 mg in postmenopausal women with low BMD who had 
previously been treated with alendronate (McClung et al 
2007), the majority (78.7%) of patients expressed prefer-
ence for once yearly infusion over weekly oral therapy. 
The clear preference was seen in both treatment groups of 
this randomized, double-blind, double-dummy study, with 
respect to the other parameters of convenience, such as 
lifestyle ﬁ  t and willingness to take for an extended period 
of time. Answers were provided by patients under the 
assumption that the overall safety and effectiveness of the 
two treatment options were similar. Even the majority of 
patients who had AEs within 3 days of study drug infusion 
still preferred a yearly infusion (78.1%). Given the low 
adherence associated with oral treatment options currently 
available for osteoporosis, the ﬁ  ndings of this study are 
particularly promising (Omizo et al 2006).
The annual infusion ensuring “adherence” for full 
12 months, despite the pharmacological speciﬁ  cs for zoledro-
nate, might also account for the impressive fracture reduction 
potential shown for zoledronate in the HORIZON-PFT trial 
(Black et al 2007). 90.8% of patients randomized to zoledro-
nate received all three infusions, far more than reported from 
any other fracture outcome study with other bisphosphonates. 
This represents 100% compliance to the bisphosphonate 
therapy for 3 years – the minimum treatment duration as 
recommended by most guidelines worldwide – in 9 of 10 
patients. This treatment option could be useful especially, 
but not only, in patients known for their low compliance to 
any long-term drug treatment:
-  patients at higher ages,
- memory  disorders,  dementia,
- multi-medication,
- problems to stay upright or fast as required for oral 
bisphosphonates,
-  UGIT co-morbidity or UGIT AEs with oral bisphosphonates.Clinical Interventions in Aging 2008:3(2) 293
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Collectively, data conﬁ  rm that one aspect of patient 
non-adherence to oral bisphosphonates that can be changed is 
dosing frequency or IV application. It has been demonstrated 
that this preference for reduced dosing frequency inﬂ  uences 
adherence (Reginster and Rabenda 2006).
Patient preferences and considerations
Despite the data of clinical studies and surveys on patient pref-
erence, it is important that physicians consider patient prefer-
ence individually when prescribing treatment for osteoporosis 
on case by case basis to ensure that the disease is effectively 
managed for the long-term beneﬁ  t of the patient.
Patients with osteoporosis want an effective and well-
tolerated treatment. However, even with the proven efﬁ  cacy 
and safety proﬁ  les of the bisphosphonates from clinical 
trials, patients still do not remain on treatment. Therefore, 
other strategies are needed to improve therapeutic adherence. 
Improved communication between physicians and their 
patients may be one way to help (Reginster and Rabenda 
2006; Kamatari et al 2007).
The IMPACT (Improving the Measurements of Persis-
tence on Actonel Treatment) study showed that a signiﬁ  cant 
improvement in persistence was achieved whenever patients 
were given a positive message regarding their response 
to treatment, in this case verbal feedback regarding their 
bone turnover marker (BTM) results. Intervention based 
on a good BTM response was associated with a signiﬁ  cant 
improvement in persistence (HR 0.71; 95% CI 0.53–0.95). 
Persistence was unchanged or lower when reinforcement 
was based on a stable or poor BTM response, respectively 
(Delmas et al 2007).
According to Reginster and Rabenda in their 2006 
review on patient preference, it has also been indicated in 
other chronic conditions that involving patients in treatment 
decisions and matching the decisions with the preferences 
improves patient satisfaction, adherence, perception of health 
and, ultimately, the outcomes (Lopes et al 2001; Janz et al 
2004; Jahng et al 2005; Lin et al 2005).
In the IOF Adherence Gap Report (2005), nine out of ten 
patients surveyed acknowledged that osteoporosis is a serious 
disease – a ﬁ  nding corresponding to the response provided 
by the same proportion of physicians (88%). Despite the 
apparent agreement on this point, there still seem to be gaps 
in understanding between patients and physicians. Physicians 
are aware that a large proportion of their patients discontinue 
treatment; however, 71% reported that they did not know 
why patients stopped therapy, 86% were unsure about how 
best to motivate patients to continue their medication, and 
41% had attempted to motivate their patients by stressing 
the possibility of risks and complications. With respect to 
the last, interviews with the affected women in this survey 
reveal that negative motivators may not necessarily be the 
best approach, as what motivated women in fact most was 
to know that they were doing something to help themselves. 
This would seem to point towards the need to positively 
encourage patients by highlighting the beneﬁ  ts of treatment 
rather than making them afraid of the negative consequences 
of non-adherence. Less frequent oral dosing emerged as 
another popular option as a means of improving adherence 
to treatment, because it had the potential to reduce both, the 
inconvenience surrounding current dosing regimens and the 
frequency of side effects (IOF 2005). It might be assumed 
that similar ﬁ  ndings could be attributed to the once-yearly or 
quarterly IV application instead of monthly or weekly oral 
regimens since IV bisphosphonates were not yet available at 
the time of the survey.
Conclusions
Nitrogen-containing bisphosphonates are potent inhibitors 
of osteoclastic bone resorption and share, as a class, simi-
lar pharmacological properties. They have been proven in 
numerous outcome trials in postmenopausal osteoporosis 
to signiﬁ  cantly reduce the incidence of vertebral fractures 
(alendronate, ibandronate, risedronate, zoledronate). Risk 
reduction for non-vertebral and hip fractures has been shown 
for risedronate and zoledronate in ITT populations, and for 
alendronate in sub-group analyses. Also ibandronate has 
shown non-vertebral fracture risk reduction in a post-hoc 
sub-group analysis. With proven efﬁ  cacy and an overall 
beneﬁ  cial safety proﬁ  le, nitrogen-containing bisphosphonates 
are considered a treatment of ﬁ  rst choice in postmenopausal 
osteoporosis. Treatment effects in an individual patient and 
cost-effectiveness in public health perspective are vitally 
dependent on long-term patient adherence, on compliance 
and persistence. As compliance and persistence with daily 
oral bisphosphonates are suboptimal in many patients and 
fracture incidence is increased in these patients, there is a 
need to improve overall adherence to bisphosphonate treat-
ment to achieve maximum treatment effects. One option is to 
extend dosing intervals to weekly (alendronate, risedronate) 
or monthly (ibandronate) oral regimens. Another alternative 
is IV instead of oral application (ibandronate, zoledronate). 
Less frequent oral regimens are generally preferred by major-
ity of patients. First studies have shown that the acceptance 
could be further improved by IV bisphosphonates with their 
beneﬁ  t of only quarterly or even once-yearly application.Clinical Interventions in Aging 2008:3(2) 294
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Physicians should make use of the ever increasing number 
of treatment options and alternatives with different nitrogen-
containing bisphosphonates. Their treatment decisions should 
be based on anti-fracture efﬁ  cacy data ﬁ  rst. However, to ensure 
best possible patient adherence, they should take into consid-
eration from the very beginning individual patient conditions 
affecting compliance and persistence (such as age, multi-
medication, gastrointestinal co-morbidity) as well as patient 
preferences (such as lifestyle, convenience). It is important 
that physicians discuss all options with their patients before a 
treatment choice is made and monitor patient adherence, par-
ticularly in oral bisphosphonates. IV bisphosphonates are, in 
general, a new and promising alternative to oral regimens.
To achieve maximum treatment beneﬁ  ts for patients with 
osteoporosis in a long-term perspective, alternative treat-
ment options offered by the different nitrogen-containing 
bisphosphonates with different applications and dosing 
intervals should be used consciously and, consequently, in 
close co-operation between physicians and patients. Chances 
and choice have never been better.
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